# IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

> **NCT04298879** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 81 (actual)

## Conditions studied

- Indolent Non-hodgkin Lymphoma

## Interventions

- **DRUG:** IBI376

## Key facts

- **NCT ID:** NCT04298879
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-07
- **Primary completion:** 2021-07-27
- **Final completion:** 2023-11-21
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298879, "IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04298879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*